Gemeprost

Summary

Gemeprost (CHEMBL1908315) is an approved small molecule (ATC G02AD03); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G02AD03
• Indications: 1 condition
• Chemistry: 394.5 Da · C23H38O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1908315
Name	Gemeprost
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5282237
ATC	G02AD03
Molecular formula	C23H38O5
Molecular weight	394.5
InChIKey	KYBOHGVERHWSSV-VNIVIJDLSA-N

SMILES: CCCCC(C)(C)[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCC/C=C/C(=O)OC)O)O

IUPAC name: methyl (E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-2-enoate

Also known as: Cervagem, Gemeprost, Preglandin, SC-37681, U-37026, GEMEPROST

Patent coverage: 459 distinct patent families (1,528 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).